Suncor Energy Inc. (SU) Stock Price Today
Aura AI Summary
Key Stats
- $79.33BMarket Cap
- -Volume
- EnergySector
- $69.7352W High
- $38.1752W Low
- -Typical Hold Time
- $87.56BEnterprise Value
- 2.51%Div Yield
- -Trading Activity
Track Suncor Energy Inc. (SU) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Suncor Energy Inc. has traded between a low of $38.17 and a high of $69.73, highlighting its annual price range. Buy and sell Suncor Energy Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Most Recent News
New AI tech cuts energy use up to 50% and boosts server capacity on existing NVIDIA hardware.
Trust Carbon Infrastructure unveiled its HXS compute-efficiency layer, which reduces energy consumption by up to 50.5% and increases server throughput by 167% on NVIDIA H100 GPUs without changing AI model outputs. Tested on models from Alibaba, Meta,...

FDA clears Medicus Pharma's Phase 2b trial for SkinJect to treat Gorlin syndrome patients
Medicus Pharma received FDA clearance to start a Phase 2b clinical trial for SkinJect, a minimally invasive treatment targeting basal cell carcinoma in Gorlin syndrome patients. This rare genetic disorder causes multiple basal cell lesions, with no c...

Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.
Collegium Pharmaceutical is transforming from a pain-management company to a central nervous system (CNS) platform by acquiring AZSTARYS, an ADHD drug franchise. The $650 million acquisition, funded by cash and debt, is projected to generate $60–70 m...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.